UBS Group’s TCR2 Therapeutics Inc. Common Stock TCRR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-234
| Closed | -$351 | – | 9024 |
|
|
2023
Q1 | $351 | Buy |
+234
| New | +$351 | ﹤0.01% | 7963 |
|
|
2022
Q4 | – | Sell |
-3,699
| Closed | -$7K | – | 10137 |
|
|
2022
Q3 | $7K | Buy |
+3,699
| New | +$7K | ﹤0.01% | 7849 |
|
|
2022
Q1 | – | Sell |
-9,701
| Closed | -$45K | – | 9947 |
|
|
2021
Q4 | $45K | Sell |
9,701
-45,027
| -82% | -$209K | ﹤0.01% | 5920 |
|
|
2021
Q3 | $466K | Buy |
54,728
+39,466
| +259% | +$336K | ﹤0.01% | 3779 |
|
|
2021
Q2 | $251K | Sell |
15,262
-38,808
| -72% | -$638K | ﹤0.01% | 4185 |
|
|
2021
Q1 | $1.19M | Buy |
54,070
+52,582
| +3,534% | +$1.16M | ﹤0.01% | 3206 |
|
|
2020
Q4 | $46K | Buy |
1,488
+1,209
| +433% | +$37.4K | ﹤0.01% | 5275 |
|
|
2020
Q3 | $6K | Sell |
279
-4,890
| -95% | -$105K | ﹤0.01% | 6375 |
|
|
2020
Q2 | $79K | Sell |
5,169
-1,666
| -24% | -$25.5K | ﹤0.01% | 4669 |
|
|
2020
Q1 | $53K | Sell |
6,835
-7,618
| -53% | -$59.1K | ﹤0.01% | 4912 |
|
|
2019
Q4 | $206K | Buy |
14,453
+5,481
| +61% | +$78.1K | ﹤0.01% | 4591 |
|
|
2019
Q3 | $135K | Buy |
8,972
+7,375
| +462% | +$111K | ﹤0.01% | 4658 |
|
|
2019
Q2 | $23K | Buy |
1,597
+1,565
| +4,891% | +$22.5K | ﹤0.01% | 5654 |
|
|
2019
Q1 | $1K | Buy |
+32
| New | +$1K | ﹤0.01% | 6752 |
|